Last updated: September 17, 2026
Carbomer 934 is a crosslinked polyacrylic-acid excipient used primarily as a viscosity modifier, suspending agent, emulsifier, gel former, and bioadhesive in pharmaceutical and topical products. Its commercial position is mature rather than high-growth. Demand is tied to ophthalmic gels, dermatological formulations, oral liquids, gels, and selected controlled-release systems.
The market has limited public financial transparency. Carbomer 934 is sold as part of broader excipient portfolios, and manufacturers generally do not disclose revenue by grade. Lubrizol’s Carbopol 934P is the best-known pharmaceutical-grade reference product, but Lubrizol does not report Carbopol 934P revenue separately. Financial analysis therefore depends on pharmaceutical excipient segment data, formulation demand, capacity, pricing, and supplier concentration rather than direct product sales.
What is Carbomer 934 and how is it used?
Carbomer 934 is a high-molecular-weight, crosslinked polymer of acrylic acid. Neutralization causes the polymer to swell and produce high viscosity at low use levels. The material is commonly supplied as a fine white powder and is processed by dispersion, hydration, and neutralization.
What pharmaceutical functions does Carbomer 934 perform?
| Function |
Formulation application |
| Viscosity modifier |
Ophthalmic gels, topical creams, lotions, oral liquids |
| Suspending agent |
Oral suspensions and dispersed dosage forms |
| Gel former |
Dermatological and mucosal preparations |
| Emulsion stabilizer |
Creams, lotions, and semisolid products |
| Bioadhesive |
Ocular, nasal, buccal, and mucosal delivery |
| Controlled-release aid |
Selected oral and topical delivery systems |
Carbomer 934 is not an active pharmaceutical ingredient. It has no therapeutic indication or independent FDA exclusivity period. Its value comes from formulation performance, regulatory acceptability, supply reliability, and the cost of replacing it in a validated product.
Carbomer 934 should be distinguished from Carbopol 934P. The "P" designation generally identifies a pharmaceutical-grade product intended for drug formulations and associated compendial requirements. Carbomer 934 products can differ in residual solvent profile, heavy-metal limits, microbiological controls, particle characteristics, viscosity, and documentation.
What is the market size and financial trajectory for Carbomer 934?
No audited public dataset reports global revenue specifically for Carbomer 934. Public market reports usually combine carbomers with acrylic rheology modifiers, polyacrylic-acid polymers, personal-care thickeners, or broader pharmaceutical excipients. Those categories are not interchangeable.
The most defensible financial view is that Carbomer 934 is a mature, specialty excipient subsegment with moderate volume growth, stable-to-rising value growth, and periodic price pressure.
Market trajectory by driver
| Driver |
Effect on Carbomer 934 demand |
| Growth in topical generics |
Positive |
| Expansion of ophthalmic gels |
Positive |
| Oral liquid manufacturing |
Positive, but formulation-specific |
| Biologics manufacturing |
Limited direct effect |
| Premium dermatology products |
Positive |
| Low-cost regional suppliers |
Negative for unit pricing |
| Supplier qualification requirements |
Supports incumbent pricing |
| Substitution by alternative polymers |
Moderate competitive pressure |
| Pharmaceutical outsourcing |
Positive for qualified excipient demand |
Demand growth is more likely to come from formulation count and geographic expansion than from large increases in the quantity used per product. Carbomer is potent at low concentrations, so volume growth can remain modest even when the number of finished products increases.
How does Carbomer 934 generate supplier revenue?
Supplier economics are based on several layers:
- Base polymer production and crosslinking.
- Pharmaceutical-grade purification and testing.
- Milling and particle-size control.
- Batch documentation and regulatory support.
- Technical service and formulation assistance.
- Qualification and change-control management.
The final price therefore reflects more than acrylic-acid raw material costs. Pharmaceutical customers pay for consistency, compendial compliance, traceability, regulatory files, and the cost of switching an approved formulation.
Public company disclosures generally aggregate these activities into specialty chemicals, pharmaceutical ingredients, or personal-care ingredients. Lubrizol is owned by Berkshire Hathaway and does not disclose Carbopol product revenue as a separate reporting line. Ashland reports pharmaceutical and personal-care ingredients within broader business segments rather than publishing Carbomer 934 sales. This prevents a reliable standalone revenue or margin calculation. [1, 2]
Which companies manufacture or supply Carbomer 934?
Lubrizol is the most visible global supplier through the Carbopol brand. Other suppliers compete with carbomer and polyacrylic-acid grades, but commercial equivalence must be assessed grade by grade.
Principal competitive groups
| Supplier or group |
Relevant competitive position |
| Lubrizol |
Carbopol brand, broad pharmaceutical and personal-care portfolio, strong regulatory and technical support |
| Ashland |
Pharmaceutical excipients and specialty formulation polymers; competes across rheology and delivery applications |
| Corel Pharma Chem |
Pharmaceutical excipient supplier with carbomer offerings and regional reach |
| Wanhua Chemical and other Asian producers |
Cost-driven competition, regional supply expansion, and alternative carbomer grades |
| Specialty distributors |
Local inventory, documentation support, and secondary sourcing |
| Contract manufacturers |
Indirect demand through finished-dose production |
The commercial comparison is not based only on nominal viscosity. Customers evaluate neutralization response, clarity, yield value, electrolyte tolerance, preservative compatibility, microbial control, residual impurities, particle size, and lot-to-lot reproducibility.
How strong is the supplier position of Lubrizol Carbopol 934P?
Lubrizol’s position is strongest where the excipient is embedded in an approved drug product and the customer values low regulatory risk. A product developer may select an established grade because it has a long history of use, available regulatory documentation, and known performance in FDA-reviewed formulations.
That position is weaker in new products, nonprescription products, cosmetics, and markets where customers can qualify lower-cost alternatives. A competitor does not need to reproduce the brand name. It needs to demonstrate comparable functionality and support a customer’s regulatory change assessment.
What patents protect Carbomer 934?
Carbomer 934 is not protected by a current composition-of-matter patent in the ordinary commercial sense. The underlying crosslinked polyacrylic-acid technology is decades old, and any early foundational patents have expired.
What intellectual property still matters?
Current commercial protection is more likely to involve:
- Manufacturing conditions.
- Crosslinker selection and concentration.
- Particle-size distribution.
- Purification methods.
- Residual impurity control.
- Grade-specific specifications.
- Packaging and moisture-control systems.
- Formulation patents using carbomer in a particular drug product.
- Trademarks such as Carbopol.
- Confidential know-how and customer qualification files.
A patent covering a finished pharmaceutical formulation may require carbomer or a functionally defined polymer. That patent would protect the drug product or method of use, not Carbomer 934 as a commodity excipient.
Does Carbomer 934 have FDA Orange Book exclusivity?
No. Carbomer 934 is an excipient and is not independently listed in the FDA Orange Book as a drug product with patent or regulatory exclusivity. Orange Book relevance arises only when Carbomer 934 is included in a listed finished product and a sponsor asserts a formulation, method-of-use, or other drug-product patent. [3]
What is the FDA regulatory status of Carbomer 934?
Carbomers are established pharmaceutical excipients, but FDA status depends on the precise grade, route, concentration, formulation, and product context.
FDA regulatory considerations
| Regulatory issue |
Commercial implication |
| Inactive Ingredient Database listing |
Supports precedent for specific routes and dosage forms |
| USP-NF compliance |
Provides a recognized quality standard |
| Drug Master File or regulatory package |
Reduces customer filing burden |
| Grade-specific identity |
Prevents automatic substitution between grades |
| Residual impurity profile |
Affects qualification and toxicological review |
| Microbial controls |
Important for aqueous and semisolid products |
| Change control |
Can trigger customer comparability work |
| Route-specific precedent |
Does not automatically authorize every use |
The FDA Inactive Ingredient Database is a key reference for determining whether a carbomer grade or related carbomer entry has precedent in a particular route and dosage form. An IID entry does not constitute blanket approval for every concentration or application. Sponsors must still demonstrate quality, safety, compatibility, and performance in the finished product. [4]
USP-NF and other pharmacopoeial standards are commercially important because they provide identity and quality benchmarks. European customers may also evaluate compliance with the European Pharmacopoeia and excipient risk-management expectations. [5]
What formulations are protected by Carbomer 934?
Carbomer 934 can be commercially important in formulations where viscosity, suspension stability, clarity, spreadability, or residence time affects product performance.
High-value application areas
Ophthalmic products
Carbomer-based ophthalmic gels can increase ocular residence time and reduce dosing frequency. The main qualification issues are clarity, sterility compatibility, osmolality, preservative interaction, drop size, and patient comfort.
Dermatological products
Topical gels, creams, and lotions use carbomer to control rheology and improve application. Dermatology is a significant demand center because small changes in polymer level can alter spreadability, drug release, and sensory properties.
Oral liquids
Carbomer may stabilize suspensions and modify viscosity. The formulation must control taste, mouthfeel, sedimentation, redispersibility, and interaction with salts or active ingredients.
Mucosal and bioadhesive delivery
Carbomer’s mucoadhesive properties support selected nasal, buccal, vaginal, and other mucosal systems. These applications may offer higher technical value than conventional topical thickening but require more extensive product-specific testing.
Controlled-release formulations
Carbomer can contribute to matrix formation or release-rate control. The value depends on whether the polymer is essential to the release mechanism and whether the formulation patent defines the polymer broadly or narrowly.
When does Carbomer 934 lose exclusivity?
Carbomer 934 has no drug-style exclusivity date. Its underlying technology is effectively off-patent, and generic or alternative suppliers can compete subject to quality and customer qualification requirements.
The relevant commercial barrier is not patent expiry. It is switching friction.
Main barriers to substitution
- Customer validation of an alternative grade.
- Comparative viscosity and rheology testing.
- Drug-release or bioadhesion studies.
- Stability data.
- Regulatory notification or filing requirements.
- Supplier audits.
- Change-control approval.
- Manufacturing-line compatibility.
- Risk of finished-product failure.
For an approved drug, replacing the excipient can require a postapproval change assessment under FDA chemistry, manufacturing, and controls requirements. The regulatory burden varies with the product, route, formulation role, and scale of the change. [6]
What generic entry risks exist for Carbomer 934-containing products?
Generic entry risk depends on the finished drug, not on Carbomer 934 itself.
Risk factors for finished products
| Factor |
Generic entry effect |
| Simple topical formulation |
Higher entry potential |
| Complex ophthalmic gel |
Lower initial entry potential |
| Critical bioadhesive function |
Higher development burden |
| Narrow therapeutic index |
Greater equivalence complexity |
| Formulation patent claims |
Delays or limits entry |
| Method-of-use patent claims |
May support litigation |
| Low annual sales |
Reduces generic incentive |
| Multiple qualified excipient suppliers |
Lowers manufacturing barriers |
Carbomer 934 usually does not create a standalone barrier to generic entry. It can contribute to complexity when the polymer controls drug release, residence time, viscosity, or product performance that must be demonstrated in an abbreviated application.
Which patent litigation and Paragraph IV challenges affect Carbomer 934?
There is no broad, standalone Paragraph IV litigation category for Carbomer 934. Paragraph IV challenges are filed against patents listed for finished drug products, not against the excipient as an independent product.
Relevant disputes may concern:
- A topical gel formulation.
- An ophthalmic gel vehicle.
- A controlled-release matrix.
- A specific polymer concentration range.
- A method of treating a disease using a carbomer-containing formulation.
- A manufacturing process for the finished drug.
A supplier’s trademark or grade designation can also create commercial disputes, but those are distinct from Hatch-Waxman patent litigation.
How does Carbomer 934 compare with competing excipients?
| Excipient class |
Advantages relative to Carbomer 934 |
Limitations |
| HPMC |
Broad oral and topical use, established regulatory history |
Different rheology and release behavior |
| CMC and sodium CMC |
Strong suspension and thickening utility |
Electrolyte sensitivity and different texture |
| Poloxamers |
Thermoresponsive and solubilizing properties |
Lower viscosity in some applications |
| Xanthan gum |
Effective at low levels, useful in oral liquids |
Microbial and sensory considerations |
| Cellulose ethers |
Broad formulation history |
May provide less clear gels |
| Acrylate copolymers |
Tailored rheology and adhesion |
Grade-specific qualification required |
Carbomer 934 is strongest where clear gels, high viscosity at low concentration, and predictable neutralization are central. It is less dominant where electrolyte tolerance, natural-origin positioning, or low-cost oral suspension performance drives selection.
What manufacturing and supply-chain risks affect Carbomer 934?
Manufacturing depends on acrylic-acid supply, crosslinking chemistry, solvent handling, drying, milling, and quality control. The main risks are:
- Raw-material price volatility.
- Energy-intensive drying.
- Batch contamination.
- Particle-size variation.
- Crosslinker or residual impurity variability.
- Transport and inventory disruption.
- Concentration of pharmaceutical-grade capacity.
- Regulatory impact from manufacturing-site changes.
Pharmaceutical customers often maintain dual sourcing for business continuity, but dual sourcing is not automatic. A second supplier must demonstrate equivalence, and the finished-product manufacturer may need a formal comparability package.
Geographic coverage is strongest in North America, Europe, and Asia, with regional distributors supporting smaller markets. Asian suppliers can pressure pricing, but regulated-market adoption depends on documentation, audits, compendial compliance, and consistent supply history.
What is the commercial outlook for Carbomer 934?
The outlook is stable with moderate growth in value and limited exposure to breakthrough demand. Growth should come from:
- Generic dermatology.
- Ophthalmic gels.
- OTC topical products.
- Mucosal delivery systems.
- Pharmaceutical outsourcing.
- Emerging-market drug manufacturing.
- Reformulation of liquid and semisolid products.
Margin pressure should come from regional alternatives, broader carbomer capacity, and customer qualification of second sources. Premium pricing remains defensible for suppliers that provide strong documentation, technical service, batch consistency, and established regulatory precedent.
The most attractive commercial position is not commodity volume. It is supply into approved products where switching requires validation and regulatory review.
Key Takeaways
- Carbomer 934 is a mature crosslinked polyacrylic-acid excipient used in topical, ophthalmic, oral, mucosal, and controlled-release formulations.
- Carbopol 934P is the principal pharmaceutical-grade reference associated with Lubrizol.
- No public audited source reports Carbomer 934 revenue separately.
- Lubrizol and other suppliers benefit from qualification, documentation, and switching costs rather than active patent exclusivity.
- Carbomer 934 has no independent Orange Book listing or Hatch-Waxman exclusivity period.
- Finished-product patents may cover formulations that use carbomer, but those patents do not protect the excipient itself.
- Generic-entry risk is determined by the drug formulation, route, release mechanism, and listed patents.
- The financial trajectory is likely stable to moderately growing in value, with pricing constrained by alternative suppliers and customer second-source programs.
- The strongest demand areas are ophthalmic gels, dermatological products, oral liquids, and specialized mucosal delivery.
- Manufacturing know-how, grade consistency, regulatory documentation, and customer qualification are the principal commercial barriers.
FAQs
Is Carbomer 934 the same as Carbopol 934P?
No. Carbomer 934 is a polymer grade or compendial description, while Carbopol 934P is a branded pharmaceutical-grade product. Specifications and regulatory documentation must be compared directly.
Is Carbomer 934 safe for ophthalmic formulations?
Carbomer can be used in ophthalmic products when the specific grade, concentration, sterility process, impurities, and finished formulation meet regulatory and product-performance requirements. General carbomer status does not automatically approve every ophthalmic use.
Can manufacturers freely substitute another carbomer for Carbomer 934?
No. Substitution generally requires comparative testing, supplier qualification, stability assessment, and a regulatory change evaluation. The required work depends on the product and the excipient’s functional role.
Does Carbomer 934 qualify as a biologic manufacturing excipient?
It is not a biologic active ingredient. Its use in biologic or advanced delivery systems would require product-specific compatibility, impurity, and regulatory assessment.
Are Carbomer 934 prices expected to rise?
Pricing depends on acrylic-acid costs, energy, capacity, logistics, grade qualification, and supplier competition. Premium pharmaceutical grades may retain pricing support, while standard grades face greater pressure from regional producers.
References
-
Berkshire Hathaway Inc. (2024). 2023 annual report. Berkshire Hathaway Inc.
-
Ashland Inc. (2024). 2023 annual report. Ashland Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
-
U.S. Food and Drug Administration. (2014). Changes to an approved NDA or ANDA: Guidance for industry. FDA.
